Atara Biotherapeutics Inc Revenue Growth Rates (ATRA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Atara Biotherapeutics Inc   (NASDAQ: ATRA)
 

ATRA's Revenue Growth by Quarter and Year

Atara Biotherapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ATRA/growth
https://api.csimarket.com/api/v1/companies/ATRA/fundamentals
https://api.csimarket.com/api/v1/companies/ATRA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ATRA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.22
2nd Quarter June 0.63
1st Quarter March 0.57
FY 2.42

ATRAs Annual Revenue
Atara Biotherapeutics Inc 's Revenue in the fiscal year 2025 $ 121.46 millions
Atara Biotherapeutics Inc 's Revenue in the fiscal year 2024 $ 259.99 millions
Atara Biotherapeutics Inc 's Revenue in the fiscal year 2023 $ 22.57 millions
Atara Biotherapeutics Inc 's Revenue in the fiscal year 2022 $ 63.57 millions
Atara Biotherapeutics Inc 's Revenue in the fiscal year 2021 $ 20.34 millions




ATRA Revenue third quarter 2026 Y/Y Growth Comment
Atara Biotherapeutics Inc reported drop in Revenue in the third quarter 2026 by -66.56% to $ 1.22 millions, from the same quarter in 2025.
The fall in the third quarter 2026 Atara Biotherapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 224.65%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue growth. While Atara Biotherapeutics Inc ' s Revenue meltdown of -66.56% ranks overall at the positon no. 2936 in the third quarter 2026.


ATRA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -66.56 %
2nd Quarter June -96.44 %
1st Quarter March -99.42 %
FY   -

Financial Statements
Atara Biotherapeutics Inc 's third quarter 2026 Revenue $ 1.22 millions ATRA's Income Statement
Atara Biotherapeutics Inc 's third quarter 2025 Revenue $ 3.66 millions Quarterly ATRA's Income Statement


ATRA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 94.29 %
2nd Quarter June 10.53 %
1st Quarter March -64.15 %
FY (Year on Year)   -


Back to ATRA Growth rate Comparisons >> Back to ATRA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #410
Overall #2936

Revenue Y/Y Growth Statistics
High Average Low
1184.89 % 224.65 % -97.79 %
(Sep 30 2024)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #410
Overall #2936
Revenue Y/Y Growth Statistics
High Average Low
1184.89 % 224.65 % -97.79 %
(Sep 30 2024)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Atara Biotherapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1824.89 % 134 % -95.04 %
(Mar 31 2023)  


ATRA's III. Quarter Q/Q Revenue Comment
Atara Biotherapeutics Inc achieved in the III. Quarter 2026 below company average Revenue jump of 94.29% quarter on quarter, to $ 1.22 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -79.35% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Atara Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 795.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #124
Overall #795
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #124
Overall #795
Revenue Q/Q Growth Statistics
High Average Low
1824.89 % 134 % -95.04 %
(Mar 31 2023)  


ATRA's III. Quarter Q/Q Revenue Comment
Atara Biotherapeutics Inc achieved in the III. Quarter 2026 below company average Revenue jump of 94.29% quarter on quarter, to $ 1.22 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -79.35% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Atara Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 795.


Atara Biotherapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 4.02
Y / Y Revenue Growth (TTM) -98.13 %
Year on Year Revenue Growth Overall Ranking # 90
Seqeuential Revenue Change (TTM) -37.71 %
Seq. Revenue Growth (TTM) Overall Ranking # 2936


Cumulative Revenue growth Comment
Atara Biotherapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -98.13% year on year, at Sep 30 2026 compare to the -97.79% decrease at Jun 30 2026. If the Atara Biotherapeutics Inc 's fiscal year would end at Sep 30 2026, annual Revenue would be $4 millions.

Within the Healthcare sector 28 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 53 to 90.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 29
Overall # 90

Revenue TTM Y/Y Growth Statistics
High Average Low
1184.89 %
 224.65 %
-97.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 410
S&P 500 # 2936
Cumulative Revenue growth Comment
Atara Biotherapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -98.13% year on year, at Sep 30 2026 compare to the -97.79% decrease at Jun 30 2026. If the Atara Biotherapeutics Inc 's fiscal year would end at Sep 30 2026, annual Revenue would be $4 millions.

Within the Healthcare sector 28 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 53 to 90.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 29
Overall # 90

Revenue TTM Y/Y Growth Statistics
High Average Low
1184.89 %
224.65 %
-97.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 410
S&P 500 # 2936




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ATRA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Sutro Biopharma Inc -6.14%$ -6.138 millions
Zai Lab Limited-6.79%$ -6.794 millions


About Atara Biotherapeutics Inc Revenue Growth Rates (ATRA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Atara Biotherapeutics Inc (CIK 1604464).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-125192
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Atara Biotherapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.